TITLE: Prediction of Preeclampsia from Clinical and Genetic Risk Factors in Early and

Late Pregnancy Using Machine Learning and Polygenic Risk Scores

AUTHORS: Vesela P Kovacheva^{1*}, Braden W Eberhard^{1*}, Raphael Y Cohen^{1,2}, Matthew

Maher³, Richa Saxena^{3,4}, Kathryn J Gray^{3,5}

*Co-first authors

¹Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's

Hospital, Harvard Medical School, Boston, MA

²PathAI, Boston, MA

³Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA

⁴Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital,

Harvard Medical School, Boston, MA

⁵Division of Maternal-Fetal Medicine, Brigham and Women's Hospital, Harvard Medical

School, Boston, MA

CORRESPONDING AUTHOR:

Vesela P. Kovacheva MD PhD

Department of Anesthesiology, Perioperative and Pain Medicine,

Brigham and Women's Hospital, Harvard Medical School

75 Francis St, L1, Boston, MA 02115

Email: vkovacheva@bwh.harvard.edu

ABBREVIATED TITLE (50 characters): Genetic and clinical factors predict preeclampsia risk

KEYWORDS: preeclampsia, pregnancy, blood pressure, polygenic risk scores, machine

learning, risk factors

ABSTRACT

Background

Preeclampsia, a pregnancy-specific condition associated with new-onset hypertension after 20 weeks gestation, is a leading cause of maternal and neonatal morbidity and mortality. Predictive tools to understand which individuals are most at risk are needed.

Methods

We identified a cohort of N=1,125 pregnant individuals who delivered between 05/2015-05/2022 at Mass General Brigham hospitals with available electronic health record (EHR) data and linked genetic data. Using clinical EHR data and systolic blood pressure polygenic risk scores (SBP PRS) derived from a large genome-wide association study, we developed machine learning (xgboost) and linear regression models to predict preeclampsia risk.

Results

Pregnant individuals with an SBP PRS in the top quartile had higher blood pressures throughout pregnancy compared to patients within the lowest quartile SBP PRS. In the first trimester, the most predictive model was xgboost, with an area under the curve (AUC) of 0.73. Adding the SBP PRS to the models improved the performance only of the linear regression model from AUC 0.70 to 0.71; the predictive power of other models remained unchanged. In late pregnancy, with data obtained up to the delivery admission, the best performing model was xgboost using clinical variables, which achieved an AUC of 0.91.

Conclusions

Integrating clinical and genetic factors into predictive models can inform personalized preeclampsia risk and achieve higher predictive power than the current practice. In the future, personalized tools can be implemented in clinical practice to identify high-risk patients for preventative therapies and timely intervention to improve adverse maternal and neonatal outcomes.

NON-STANDARD ABBREVIATIONS AND ACRONYMS

AUC, area under the receiver operator curve

BMI, body mass index

DBP, diastolic blood pressure

GWAS, genome-wide association study

IUGR, intrauterine growth restriction

PCA, principle components of ancestry

PRS, polygenic risk score

SBP, systolic blood pressure

SGA, small for gestational age

SNP, single-nucleotide polymorphism

XGB, xgboost

INTRODUCTION

Preeclampsia, defined as new onset of elevated blood pressure after 20 weeks gestation, is a leading cause of maternal and neonatal morbidity and mortality worldwide. Preeclampsia affects 2-8% of all pregnancies and contributes to 26% of maternal deaths worldwide and 15% of preterm births. In the US, preeclampsia incidence is increasing and results in significant healthcare utilization. Maternal complications include end-organ damage, eclamptic seizures, and death. Fetal/neonatal complications include growth restriction and iatrogenic preterm birth. Timely diagnosis and treatment can reduce the risk for severe maternal and neonatal morbidity by 72-89%. As

Current clinical practice in patients at risk for preeclampsia is focused on close surveillance, early detection, and prompt management.^{6,7} Pregnant patients' risk for preeclampsia is assessed at the first prenatal visit and, in those at high risk, prophylaxis with low-dose aspirin and close blood pressure monitoring is recommended. Patients at high risk for preeclampsia should be managed by providers with experience in high-risk pregnancy at tertiary care hospitals.

Currently, high-risk individuals are identified based on clinical factors, including pre-existing hypertension, obesity, pregestational diabetes, advanced maternal age, multiple gestation, and prior preeclampsia; however, this approach fails to identify 46-60% of pregnancies that develop preeclampsia.⁸⁻¹⁰ Improved tools to understand each individual's personalized disease risk has the potential to markedly improve pregnancy care and clinical outcomes. Machine learning methods, based on implicitly learning relationships in large datasets allow for precise outcome prognostication and may improve preeclampsia prediction. Recent machine learning studies

about the risks of hypertensive disorders of pregnancy¹¹ and preeclampsia^{10,12} demonstrate the potential of these methods to generate highly accurate predictions.¹³ However, models published to date have low predictive power in early pregnancy when little clinical information is available; in addition, a significant number of patients – especially nulliparous patients without clinical risk factors – develop preeclampsia and, thus, fail to be identified by current models.

While preeclampsia has substantial heritability based both on maternal and fetal factors, ¹⁴ the specific genetic factors contributing to risk are just beginning to be identified, as detailed in recent genome-wide association studies (GWAS). ¹⁵⁻¹⁷ Importantly, in the largest published maternal preeclampsia GWAS, the top hits were all loci previously implicated in essential hypertension risk. In addition, several studies have demonstrated that the overall genetic architecture of maternal preeclampsia overlaps with the genetics of both systolic and diastolic blood pressure, as well as body mass index (BMI). ¹⁵⁻¹⁸ Given that essential hypertension is a known clinical risk factor for preeclampsia, ^{19,20} and genetic predisposition to hypertension is associated with increased preeclampsia risk, we hypothesized that a machine learning model incorporating both clinical risk factors and a hypertension genetic risk score (i.e., polygenic risk score, PRS, generated from GWAS summary statistics^{21,22}) could improve preeclampsia risk prediction for pregnant individuals. As PRS are associated with disease risk independent of other clinical and environmental risk factors, all factors can be combined additively in a single model.

In this study, we utilize a rich database derived from the electronic health record (EHR) of patients who have had a pregnancy in our healthcare system linked with genetic data from the biobank. We investigate the relative importance of different clinical risk factors and polygenic risk scores in the first trimester, as well as late pregnancy (before admission for delivery), to predict preeclampsia.

METHODS

The data that support the findings of this study are available from the corresponding author upon reasonable request and based on institutional guidelines.

Population

This study was approved by the Mass General Brigham Institutional Review Board, protocol # 2020P002859, with a waiver of patient consent. Pregnant patients were selected based on documentation of pregnancy greater than 20 weeks gestation and associated billing codes for cesarean or vaginal delivery. We included all available patients from May 2015 to May 2022 with genetic data available in the Mass General Brigham Biobank and analyzed each pregnancy independently. These dates were chosen as May 2015 is when our institution implemented electronic health records across all outpatient offices and inpatient sites. All data (including sociodemographic, clinical diagnoses, laboratory, vital signs, and genotyping) was obtained and analyzed using our machine learning platform, ²⁶ which extracts, transforms, and harmonizes data from multiple sources. Preeclampsia diagnosis was based on the established American College of Gynecologists and Obstetricians guidelines. All preeclampsia cases (N =87) were further validated by an experienced clinician.

Genotyping and Imputation

Genome-wide genotyping for each patient was obtained from the Mass General Brigham Biobank,²⁷ a prospective biobank launched in 2010 that contains genotyping data, samples, and questionnaires with ongoing links to tEHR. This effort is continuing, with 129,000 patients

enrolled and more than 56,000 genotyped. Genotyping was performed using one of two Illumina single nucleotide polymorphism (SNP) Arrays: the MultiEthnic Genotyping Array (containing >1.6M SNPs) or the Global Screening Array (containing > 575K SNPs). Imputation was performed using the TOPMed Imputation Server.

Polygenic Risk Scores

As systolic blood pressure (SBP) is the trait with the highest genetic correlation with the genetics of maternal preeclampsia and has the highest predictive power for future hypertensive disorders and cardiovascular disease²⁹, we created an SBP PRS using the open-source PRS-CS tool.²⁸ PRS-CS computes SNP effect sizes by high-dimensional Bayesian regression using GWAS summary statistics and a linkage disequilibrium reference panel. We selected the largest blood pressure GWAS meta-analysis to date, with over 1 million individuals,¹⁹ and used a European linkage disequilibrium reference panel with 1.1 million variants derived from samples from the 1000 Genomes Project to create SBP PRS in our study population. We categorized the PRS into quartiles of risk ranging from lowest to highest genetic risk: <25%, 25-49%, 50-75%, and >75%. We adjusted all models in which the SBP PRS was used by the first 10 principal components of ancestry (PCAs) to account for population structure.

Statistical Analyses and Definitions

For the analyses, we used all available EHR data from before conception to up to 6 weeks postpartum. Variables were treated as parametric or non-parametric according to their distribution; continuous parametric variables were expressed as mean ± SD, and nonparametric variables as the median with interquartile range (IQR). Significance was determined using the

Student's t-test and one-way ANOVA for parametric variables, the Kruskal-Wallis rank sum test

for non-parametric variables, and Fisher's exact or Chi-squared test for categorical variables. A

p-value of less than 0.05 was considered significant.

Machine Learning and Linear Regression Predictive Models

Our machine learning platform, ²⁶ which utilizes Python 3.9 (sci-kit learn library), was used for

the development of predictive models. We selected established clinical risk factors known to be

associated with preeclampsia risk in published studies and guidelines. ^{6,7,9,10,12,30} For the

predictive models, we created datasets in which only data obtained up to the selected time point

was included to minimize the risk of data leakage. When adding the SBP PRS to the models, we

considered the PRS as an independent predictor and adjusted by the first 10 PCAs. When

incorporating time-series data of blood pressure measurements across pregnancy, we divided the

pregnancy period into the following intervals: 0-14, 14-20, 20-24, 24-28, 28-32, and >32 weeks

gestation. When incorporating time-series data for pregnancy weight gain, we used the BMI

measured in the following intervals: 0-14, 14-28, and >28 weeks gestation. To assess the

discrimination performance of the models, receiver operator characteristic curves (ROC) were

developed, and the area under the curve (AUC), accuracy, sensitivity, specificity, and precision

were calculated.

RESULTS

Patient Characteristics

Of 105,673 pregnancies recorded in our healthcare system after May 2015, genotyping data were available for 1,125 pregnancies (828 unique patients), all of whom were included in the study. The patient population was multi-ancestry, with 32.7% of patients self-identifying as non-White. Of the 1,125 pregnancies, 87 had a clinical diagnosis of preeclampsia (7.8%). Patients with preeclampsia were older and more likely to be nulliparous (Table 1). Patients who self-identified as Black or Hispanic were more likely to have hypertension and were more likely to develop preeclampsia (p<0.01). In addition, patients with any hypertensive disorder, including preeclampsia, chronic, or gestational hypertension, were more likely to have a family history of chronic hypertension and preeclampsia compared to normotensive patients (p<0.01). Patients with preeclampsia delivered before the 37th week of gestation more often as compared to patients who were normotensive or who had chronic or gestational hypertension. As expected, patients with preeclampsia had the highest systolic and diastolic blood pressure during pregnancy compared to those with chronic or gestational hypertension, and normotension (p<0.01).

Polygenic Risk Scores and Maternal Blood Pressure

Patients with SBP PRS in the highest quartile had higher maximal systolic and diastolic blood pressure during pregnancy compared to patients with the lowest quartile SBP PRS (Table 2). Patients with higher SBP PRS were more likely to be diagnosed with a hypertensive disorder (preeclampsia, chronic or gestational hypertension); in contrast, patients with lower SBP PRS were more likely to be normotensive throughout gestation, p<0.05. As SBP PRS was developed using a European population, we performed a sensitivity analysis applying SBP PRS only in the subset of the population that self-identified as White. This sensitivity analysis demonstrated similar findings (Suppl. Fig. 1) and additionally identified that patients with the highest PRS had

a higher incidence of chronic hypertension. Also, patients with any hypertension diagnosis (gestational, chronic, or preeclampsia) had higher SBP PRS compared to normotensive patients (Suppl. Fig. 2).

Models to Predict Preeclampsia

We sought to predict patient preeclampsia risk at two-time points — early in pregnancy, at the first prenatal visit, and late in pregnancy, before admission for delivery. If a patient had a preeclampsia diagnosis or delivered before the time point, any data after that event was excluded to minimize data leakage. Because relationships between predictors may not be linear, we developed both linear regression and nonlinear machine learning models. Subsequently, we investigated if the addition of SBP PRS improved the predictive power of the respective model and evaluated the predictive power of each model using only clinical, only genetic, or both genetic and clinical variables, respectively (Table 3).

In early pregnancy, patients are screened for preeclampsia risk based on the presence of established clinical risk factors. We used these risk factors to develop predictive models (Suppl. Table 1). The relationship between all variables is shown in Fig 1A. The clinical linear regression model, which was developed using only clinical variables available up to 14 gestational weeks, had an AUC of 0.70 (Table 3). We also created a separate genetic linear regression model using only SBP PRS, adjusted for the PCAs; this model had a weak predictive power, AUC 0.62. Adding the SBP PRS to the clinical risk factors in a combined linear regression model increased the AUC to 0.71, which was higher than either the clinical or PRS models alone. As machine learning allows for the incorporation of multiple variables with

complex relationships, we developed a clinical xgboost model, which achieved the highest performance, AUC 0.74 (Fig 1B). In this case, adding the SBP PRS did not improve the performance. The most predictive variables in the model (determined using the Shapley interpretability method) were blood pressure, maternal age, and history of preeclampsia in a prior pregnancy (Fig 2).

By the time of delivery, more clinical information becomes available from scheduled outpatient prenatal visits, which become more frequent during the 3rd trimester (Fig. 3A). The late pregnancy models were generated using clinical information available prior to (but not after) the admission associated with preeclampsia diagnosis (Table 3). In late pregnancy, the linear regression model had an AUC of 0.84 and performed better than the early pregnancy model. Similarly, the machine learning model using clinical risk factors had the best performance of all, AUC 0.91 (Fig. 3B). At this timepoint, the addition of the SBP PRS to the clinical risk factors in the linear regression and machine learning models did not significantly improve the performance. In the best-performing model, the most predictive variables (determined using the Shapley interpretability method) were blood pressure, body mass index, uric acid level, and past medical history of renal disease (Fig. 4).

DISCUSSION

Here, we investigated the ability of machine learning and linear regression models based on electronic health records and genetic data to predict preeclampsia. Our results demonstrate that, in a multi-ethnic cohort, SBP PRSs correlate with systolic and diastolic blood pressure during pregnancy, as well as with the diagnoses of gestational and chronic hypertension. In early pregnancy, when less clinical information is available, the addition of SBP PRS to clinical risk factors improves prediction. However, in later pregnancy, when more clinical information is available and overall performance of the predictive models is improved, SBP PRS does not add to the predictive power. In both early and late pregnancy, machine learning models performed better than linear regression models; xgboost in late pregnancy was the most predictive.

In line with prior studies,²⁹ we demonstrate that SBP PRS is associated with clinically measured blood pressure and risk of hypertensive disorders. The heritability of hypertensive disorders using PRS is well established, and some recent studies have demonstrated that these findings also translate to hypertensive disorders of pregnancy.²⁰ A recent study of preeclampsia and blood pressure PRS has shown a strong disease correlation in Finnish White patients with higher PRS scores.²⁰ The maximal blood pressure measured during pregnancy was elevated in the group with the top 25% SBP PRS. We also find that gestational and chronic hypertension, as well as hypertensive disorders of pregnancy (in sensitivity analyses of White patients), are associated with higher PRS scores. We were not able to find a significant relationship between SBP PRS and preeclampsia, hypertensive medication use, and family history in our cohort, likely due to

our small sample size. In addition, SBP is only one risk factor for preeclampsia, and future studies using preeclampsia-specific or multi-trait PRS may improve the predictive capacity of polygenic scores. Also, as the current SBP PRS was generated from a White population, future studies utilizing multi-ethnic PRSs, are likely to provide additional insight.

When using only the SBP PRSs and adjusting for the first 10 principal components of ancestry, both linear and machine learning models have low predictive power. The relationships between SBP PRSs and outcomes are non-linear; individuals in the top 2.5% of the SBP PRSs have a disproportionately higher risk of disease and adverse outcomes than those in the lowest 2.5%.²⁹ We anticipated that the machine learning approaches, which have the ability to capture complex, nonlinear relationships, will achieve higher predictive power. However, the low overall and inferior performance of the xgboost model is likely due to the small number of variables included in those models and the weak association with the outcome leading to overfitting on the training data.

In early pregnancy, we demonstrate the good predictive power of the linear regression model, which is similar to or better than other studies. ^{9,10} In order to avoid overfitting with a small sample size, we selected only the variables known to be associated with a heightened risk of preeclampsia rather than using all available variables from the electronic medical record; the first approach has previously demonstrated better performance. ¹² Other models^{31,32} have achieved higher predictive power than ours; however, those included biomarkers like serum placental growth factor and uterine artery pulsatility index, which are not routinely measured in our clinical practice. In addition, we observe increased predictive power with the addition of the

clinical data is available.

The best-performing model in early pregnancy was xgboost and similarly, others have demonstrated the power of this type of machine learning model in early pregnancy to achieve accurate predictions. ^{10,12} To incorporate information about the rate of change in time-series variables like blood pressure and BMI, we included data routinely recorded at the scheduled office visits. This approach has demonstrated improved predictions. ^{10,12} The early pregnancy screening and prevention of preeclampsia has been associated with improved maternal and neonatal outcomes by 70-89%, ^{4,5} and thus, integrating this type of model in clinical practice has the potential for a high-value impact on patient care.

Similar to early pregnancy, the xgboost model in late pregnancy had higher predictive power than the linear regression model, demonstrating the superiority of the machine learning approach. Similar results have been demonstrated by others. ¹⁰ The strongest predictors for preeclampsia were blood pressure, history of renal disease, and uric acid values, which have been shown by others as well. ^{10,12} Integrating this type of model in clinical practice will aid more accurate personalized prediction and allow for referral of high-risk patients to maternal-fetal medicine specialists and planning for delivery at a tertiary care center.

When including SBP PRSs in the clinical model, we demonstrate similar to others²⁹, little to no improvement in the risk prediction. In addition to the considerations in early pregnancy, in late

pregnancy, as more clinical information is available, the patients may have expressed the genes that contribute to preeclampsia risk, or the clinical factors may have greater weight relative to the genetic factors. In the future, as better genetic tools and larger datasets become available, this approach may yield improved results.

Our study has several strengths, including detailed data for all patients from multiple visits with a low level of missingness, recent data collected in the past seven years, when the most current clinical guidelines were implemented, ⁶ and data from both tertiary and community hospitals within our large healthcare system.

Our study has several limitations. We had a small cohort of patients; however, accurate predictions using a dataset of similar size have been previously achieved. ¹² To avoid the risk of overfitting, we limited the types of analyses we performed; for example, we were not able to investigate the predictions of early-onset preeclampsia. In addition, some of the variables are based on billing codes which may be inaccurate and do not reflect disease severity. To overcome this limitation for the preeclampsia phenotype, we developed our own algorithm using the current standard of care and manually validated the cases. We used SBP PRS developed in a White population, which may not have optimally assessed risk in our multiethnic cohort. The SBP PRS we selected were developed from the largest GWAS to date, which was performed in White patients; currently, large multiethnic GWAS are lacking, which is a well-recognized limitation of the field.³³ Similarly, we were not able to externally validate this model as most large genetic biobanks lack detailed pregnancy information.

PERSPECTIVES

We demonstrate that models using clinical and genetic data in early and late pregnancy have high predictive power and can accurately predict the individual risk for preeclampsia. In addition, SBP PRSs correlate with risk factors for preeclampsia and improve the predictive power of clinical risk factors in the linear regression model in early pregnancy. Since the machine learning models using clinical data available from routine visits had the highest predictive power, these types of models can be implemented in clinical practice to function within the electronic medical records longitudinally. In this way, the risk predictions can be made available to the treating physician, in addition to the contributing factors, who can advise about prophylactic and therapeutic options, as well as referral to a maternal-fetal medicine specialist. As more pregnancy data in multi-ancestry cohorts becomes available, such strategies can be expanded.

SOURCES OF FUNDING: KJG reports funding from NIH/NHLBI grants K08 HL146963, K08 HL146963-02S1, R01 HL163234-01, R03HL162756-01, and a PJP Grant from the Preeclampsia Foundation. VPK reports funding from NIH/NHLBI grants K08 HL161326-01A1, the Foundation for Anesthesia Education and Research (FAER), Anesthesia Patient Safety Foundation (APSF), Partners Innovation, Brigham Research Institute, Connors Center IGNITE Award, and Brigham Ignite Innovation Award. RS reports funding from NIH/NHLBI grant R01 HL163234-01, and a PJP Grant from the Preeclampsia Foundation.

CONFLICTS OF INTEREST: KJG has served as a consultant to Illumina Inc., Aetion, Roche, and BillionToOne outside the scope of the submitted work. VPK reports consulting fees from Avania CRO unrelated to the current work and patent #WO2021119593A1 for control of a therapeutic delivery system which is assigned to the Mass General Brigham.

Table 1. Pregnant patient clinical characteristics

	Preeclampsia (n=87)	Chronic and gestational hypertension (n=95)	Normotensive (n=943)	P- value
Maternal age at				
delivery, y	32.9 (29.5 - 36.4)	34.4 (30.5 - 37.8)	33.5 (30.5 - 36.3)	0.27
Self-reported race				
White	60 (69%)	56 (67%)	691 (72%)	0.8
Black	13 (15%)	14 (17%)	61 (6%)	< 0.01
Other	15 (17%)	15 (18%)	211 (22%)	0.49
Self-reported ethnicity				
Hispanic	3 (3%)	4 (5%)	41 (4%)	0.91
Non-Hispanic	84 (97%)	80 (95%)	913 (96%)	1
Hospital	` ,	` ,	` ,	
Tertiary	84 (97%)	82 (98%)	886 (93%)	0.87
Community	3 (3%)	2 (2%)	68 (7%)	0.13
Gravidity	2.0 (1.0 - 3.0)	2.0 (2.0 - 4.0)	2.0 (1.0 - 3.0)	0.15
Parity	1.0 (0.2 - 2.0)	1.0 (0.5 - 2.0)	1.0 (1.0 - 2.0)	0.35
Gestational age at	, ,	, ,	,	
delivery, weeks Last BMI before	37.1 (35.3 - 38.3)	38.3 (37.0 - 39.1)	39.3 (38.6 - 40.1)	< 0.01
pregnancy, kg/m² BMI at delivery	29.3 (23.8 - 34.3)	28.7 (24.5 - 34.3)	24.9 (22.0 - 29.2)	< 0.01
(kg/m ²) Maximal SBP during	32.9 (28.6 - 37.86)	33.1 (30.0 - 37.5)	29.62 (26.3 - 33.2)	< 0.01
pregnancy, mmHg Maximal DBP during	151.0 (142.0 - 160.5)	146.0 (135.5 - 154.0)	128.0 (120.0 - 136.0)	< 0.01
pregnancy, mmHg Family history of	93.0 (87.2 - 98.7)	91.0 (84.0 - 94.7)	80.0 (74.0 - 84.0)	< 0.01
chronic hypertension Family history of	39 (45%)	55 (65%)	409 (43%)	0.012
preeclampsia	1 (1%)	4 (5%)	11 (1%)	0.028

Median (IQR) for continuous variables; n (%) for categorical variables; p-values for continuous variables based on Kruskal-Wallis rank sum test; for categorical variables based on Fisher's exact or Chi-squared test.

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure, BMI, body mass index

Table 2. Patient clinical characteristics by lowest and highest quartiles of SBP PRS

	PRS<25% (n=280)	PRS>75% (n=281)	p-value
Self-reported race			
White	134 (48%)	255 (91%)	< 0.01
Black	74 (26%)	2 (1%)	< 0.01
Other	74 (26%)	26 (9%)	< 0.01
Self-reported ethnicity			
Hispanic	19 (7%)	2 (1%)	< 0.01
Non-Hispanic	261 (93%)	279 (99%)	0.46
Chronic hypertension	14 (5%)	23 (8%)	0.14
Gestational hypertension	3 (1%)	12 (4%)	0.021
Preeclampsia	22 (8%)	24 (9%)	0.78
Any Hypertensive disorder	39	59	0.04
SBP at the first prenatal visit,			
mmHg	119.0 (112.0 - 128.0)	117.0 (110.0 - 125.7)	0.029
DBP at the first prenatal visit,			
mmHg	73.0 (68.0 - 79.0)	72.0 (66.0 - 80.0)	0.71
Maximal SBP at any time in			
pregnancy, mmHg	140.0 (130.0 - 148.0)	142.0 (133.0 - 156.0)	< 0.01
Maximal DBP at any time in			
pregnancy, mmHg	86.0 (80.0 - 92.0)	89.0 (81.0 - 96.0)	< 0.01
Antihypertensive drugs during			
pregnancy	19 (7%)	22 (8%)	0.65
Family history of chronic			
hypertension	130 (46%)	122 (43%)	0.59
Family history of preeclampsia	5 (2%)	6 (2%)	0.77

Median (IQR) for continuous variables; n (%) for categorical variables; p-values for continuous

variables based on Kruskal-Wallis rank sum test; for categorical variables based on Fisher's exact or Chi-squared test.

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure, PRS polygenic risk scores


Table 3. Power of clinical, genetic, and combined models to predict preeclampsia in the patient cohort using linear regression or machine learning models (n=1125)

Model variables	Type of model	AUC	accuracy	sensitivity	specificity	precision
Early pregnancy						
Clinical	linear	0.70	0.76	0.79	0.48	0.16
Genetic	linear	0.62	0.62	0.63	0.58	0.11
Clinical and genetic	linear	0.71	0.76	0.79	0.46	0.16
Clinical	xgboost	0.74	0.91	0.97	0.26	0.41
Genetic	xgboost	0.58	0.90	0.98	0.02	0.04
Clinical and genetic	xgboost	0.71	0.92	0.97	0.27	0.45
Late pregnancy						
Clinical	linear	0.84	0.84	0.85	0.68	0.28
Genetic	linear	0.62	0.62	0.63	0.58	0.11
Clinical and genetic	linear	0.83	0.84	0.85	0.66	0.27
Clinical	xgboost	0.91	0.93	0.97	0.43	0.57
Genetic	xgboost	0.58	0.90	0.98	0.02	0.04
Clinical and genetic	xgboost	0.91	0.92	0.96	0.44	0.55

Fig 1. Correlation matrix and preeclampsia predictive model development in early pregnancy, before 14 weeks gestation.

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure, BMI, body mass index





B.




Fig. 2 SHapley Additive exPlanations (SHAP) plot of the top variables contributing to the xgboost output in early pregnancy. The horizontal position of each point shows the impact of the feature on the model's prediction. Red, high feature value; blue low feature value.





Fig 3. Correlation matrix and preeclampsia predictive model development at late pregnancy, before the admission for delivery.

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure, BMI, body mass index.

A.



B.





Fig. 4 SHapley Additive exPlanations (SHAP) plot of the top variables contributing to the xgboost output in late pregnancy. The horizontal position of each point shows the impact of the feature on the model's prediction. Red, high feature value; blue low feature value.



SUPPLEMENTARY MATERIAL

Supplementary Methods

Limiting Data

Before training the predictive models, we excluded any data that was recorded after the date of delivery for healthy patients, or whichever came first, the preeclampsia diagnosis or delivery date for preeclamptic patients. This data constitutes the dataset for late pregnancy models, while the early pregnancy dataset also excludes any measurements taken after 13 weeks of gestation.

Feature Engineering and Selection

To capture trends in vital signs over time, measurements were assessed across different gestational age windows in pregnancy. The systolic and diastolic blood pressures (maximum, difference between maximum and minimum, and mean) were calculated before 14 weeks, 14-20, 20-24, 24-28, 28-32, 32-34, and after 34 weeks. The same measurements were calculated by trimester (<14 weeks, 14-28, and >28 weeks) for BMI since weight and height measurements were recorded less frequently. A simple variance threshold was applied to features prior to cross-validation to remove any features with a variance below the best-performing threshold of 0.04.

Cross Validation

We performed a 5-fold cross-validation using sklearn's StratifiedGroupKFold, which creates folds that tend to preserve the percentage of samples for each class as much as possible, given the constraint of non-overlapping groups between splits. ³⁴ For each training and test set created, the data were imputed, scaled, and oversampled. Missing information in binary variables was

assumed to be false, while missing continuous variables were imputed with the mean of the feature. Sklearn's MinMaxScaler was fit on the training data of each fold and modified features to contain values between 0 and 1. We applied several methods to correct for an imbalanced dataset, including SMOTE, BorderlineSMOTE, RandomOverSampler, and RandomUnderSampler. Of these methods, the RandomOversampler produced the best-performing models and was subsequently applied to all cross-validation folds.

Regression and XGB Models

Two types of models were trained with the data: a linear regression and an xgboosted ensemble. In addition to the features removed during feature selection, other highly correlated variables were combined or removed when trained on the linear regression. The xgboost ensemble consisted of 3 separate models with a maximum depth of 2, 10, and 20 with 10, 50, or 100 estimators respectively. Higher depth and number of estimators lead to an increased complexity that can be prone to overfitting. Final predictions are the equally weighted average between the individual predictions of each xgboost model. Metrics were calculated on the test set for each fold and averaged together to obtain final statistics.

Supplemental Table 1. Variables included in the first prenatal visit (early pregnancy) model.

	Preeclampsia (n=87)	No preeclampsia (n=1038) (includes normotensive, chronic, and gestational HTN)	P-value
Maternal age, y	32.9 (29.5 - 36.4)	33.6 (30.5 - 36.4)	0.29
Self-reported White race	60 (69%)	747 (72%)	0.75
Self-reported Black race	13 (15%)	75 (7%)	0.013
Self-reported Hispanic ethnicity	3 (3%)	45 (4%)	0.7
Gravidity	2.0 (1.0 - 3.0)	2.0 (1.0 - 3.0)	0.84
Parity	1.0 (0.25 - 2.0)	1.0 (1.0 - 2.0)	0.15
Interpregnancy interval, y	2.1 (1.6 - 3.2)	2.3(1.8-3.0)	0.54
In vitro fertilization	4 (5%)	43 (4%)	0.84
Multiple gestation	7 (8%)	39 (4%)	0.057
Smoking before pregnancy	21 (24%)	126 (12%)	< 0.01
Drugs of abuse before pregnancy	8 (9%)	59 (6%)	0.2
Drugs of abuse during pregnancy	6 (7%)	46 (4%)	0.3
Alcohol use before pregnancy	45 (52%)	541 (52%)	0.96
High-risk pregnancy	51 (59%)	578 (56%)	0.72
Maximal BMI before pregnancy, kg/m ²	30.8 (25.1 - 36.7)	26.7 (23.5 - 31.3)	< 0.01
Last BMI before pregnancy, kg/m ²	27.7 (23.0 - 33.9)	24.6 (21.5 – 29.0)	< 0.01
Mean BMI in the period 0-14 gestational weeks, kg/m ²	29.7 (23.7 - 34.4)	24.9 (21.9 - 29.1)	< 0.01
SBP at the first prenatal visit, mmHg	123.0 (116.0 - 138.0)	111.0 (104.0 - 120.0)	< 0.01
DBP at the first prenatal visit, mmHg	78.0 (70.0 - 82.5)	68.0 (61.0 - 74.0)	< 0.01
History of pregestational diabetes	8 (9%)	62 (6%)	0.25
History of kidney disease before pregnancy	17 (20%)	38 (4%)	< 0.01
History of gestational diabetes in a prior pregnancy	4 (5%)	54 (5%)	0.81
History of a prior high-risk pregnancy	28 (32%)	334 (32%)	1
History of autoimmune disease	7 (8%)	88 (8%)	0.89
History of preeclampsia in a prior pregnancy	23 (26%)	40 (4%)	< 0.01
Family history of hypertension	39 (45%)	464 (45%)	0.99

2	1
)	1

Family history of preeclampsia	1 (1%)	15 (1%)	0.82
Minimal platelet count in the period 0-14 gestational weeks	270 (219 - 315)	254 (217 - 288)	< 0.01
Maximal uric acid in the period	3.8 (3.3 - 3.4)	3.0 (2.3 - 3.7)	0.03
0-14 gestational weeks, mg/dL Presence of proteinuria in the period 0-14 gestational weeks	3 (3%)	3 (0%)	< 0.01
SBP PRS	1.8 (1.4 - 2.2)	1.8 (1.4 - 2.1)	0.94

Median (IQR) for continuous variables; n (%) for categorical variables; p-values for continuous variables based on Kruskal-Wallis rank sum test; for categorical variables based on Fisher's exact or Chi-squared test.

Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PCA, principle components of ancestry; PRS, polygenic risk scores.

.

Supplemental Table 2. Variables included in the late pregnancy model (before admission for delivery)

	Preeclampsia (n=87)	No preeclampsia (n=1038) (includes normotensive, chronic, and	p- value
Maternal age, y	32.3 (29.5 - 36.4)	gestational HTN) 33.5 (30.5 - 36.4)	0.29
Self-reported White race	60 (69%)	747 (72%)	0.25
Self-reported Black race	13 (15%)	75 (7%)	0.013
Self-reported Hispanic ethnicity	3 (3%)	45 (4%)	0.7
Gravidity	2.0 (1.0 - 3.0)	2.0 (1.0 - 3.0)	0.7
Parity	1.0 (0.25 - 2.0)	1.0 (1.0 - 2.0)	0.15
Interpregnancy interval, y	2.1 (1.6 - 3.2)	2.3 (1.8 – 3.0)	0.13
In vitro fertilization	4 (5%)	43 (4%)	0.84
SGA or IUGR	20 (23%)	101 (10%)	< 0.01
Multiple gestation	7 (8%)	39 (4%)	0.057
Smoking before pregnancy	21 (24%)	127 (12%)	< 0.01
Drugs of abuse before pregnancy	8 (9%)	59 (6%)	0.2
Alcohol use before pregnancy	46 (53%)	551 (53%)	0.98
High-risk pregnancy	64 (74%)	715 (69%)	0.61
Last BMI before pregnancy, kg/m ²	27.7 (23.0 - 33.9)	24.6 (21.5 – 29.0)	< 0.01
Last BMI during pregnancy before preeclampsia diagnosis or delivery, kg/m ²	32.9 (28.6 - 37.9)	30.0 (26.4 - 33.6)	< 0.01
Maximal BMI before pregnancy, kg/m ²	30.8 (25.1 - 36.7)	26.7 (23.5 - 31.3)	< 0.01
Maximal SBP during pregnancy, mmHg	151.0 (142.0 - 160.5)	129.0 (120.0 - 138.0)	< 0.01
Maximal DBP during pregnancy, mmHg	93.0 (87.2 - 98.7)	80.0 (74.0 - 85.7)	< 0.01
SBP at the first prenatal visit, mmHg	122.0 (115.5 - 136.0)	111.0 (104.0 - 120.0)	< 0.01
DBP at the first prenatal visit, mmHg	75.0 (69.0 - 81.0)	68.0 (60.0 - 74.0)	< 0.01
Prescription of antihypertensive medication during pregnancy	11 (13%)	5 (0%)	< 0.01
Diagnosis of gestational hypertension during pregnancy	17 (20%)	36 (3%)	< 0.01
History of pregestational diabetes	8 (9%)	62 (6%)	0.25
History of kidney disease before pregnancy	17 (20%)	38 (4%)	< 0.01
History of gestational diabetes in a prior pregnancy	4 (5%)	54 (5%)	0.81
History of a prior high-risk pregnancy	28 (32%)	334 (32%)	1
History of autoimmune disease	7 (8%)	88 (8%)	0.89


History of preeclampsia in a prior pregnancy	23 (26%)	40 (4%)	< 0.01
Family history of hypertension	39 (45%)	464 (45%)	0.99
Family history of preeclampsia	1 (1%)	15 (1%)	0.82
Minimal platelet count in pregnancy before preeclampsia diagnosis or delivery	212 (168 - 270)	212 (181 - 248)	0.19
Maximal uric acid in pregnancy before preeclampsia diagnosis or delivery, mg/dL	5.0 (4.1 - 5.8)	4.3 (3.5 - 5.2)	< 0.01
Proteinuria in pregnancy before preeclampsia diagnosis or delivery	12 (14%)	7 (1%)	< 0.01
SBP PRS	1.8 (1.4 - 2.2)	1.8 (1.4 - 2.1)	0.94

Median (IQR) for continuous variables; n (%) for categorical variables; p-values for continuous variables based on Kruskal-Wallis rank sum test; for categorical variables based on Fisher's exact or Chi-squared test.


Abbreviations: BMI, body mass index, SBP, systolic blood pressure, SGA, small for gestational age, IUGR, intrauterine growth retardation, DBP, diastolic blood pressure, PCA, principle components of ancestry, PRS, polygenic risk scores.

Suppl. Fig. 1 Relationship between BP and SBP PRS in patients with self-reported White race. A. PRS histogram, B. SBP at the first prenatal visit, C. DBP at the first prenatal visit, D. Max SBP during pregnancy E. Max DBP during pregnancy * p<0.05


Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; PRS polygenic risk score




Suppl. Fig. 2. Polygenic risk scores (PRS) in patients with preeclampsia (PE), chronic and gestational hypertension (HTN), and normotension.(A) All patients, (B) Patients with self-reported White race.



Suppl. Fig 3A. Missing data or data not collected in early pregnancy. Available data is shown in black.



Suppl. Fig 3B. Missing data or data not collected in late pregnancy. Available data is shown in black.



REFERENCES

- Saleem S, McClure EM, Goudar SS, Patel A, Esamai F, Garces A, Chomba E, Althabe F, Moore J, Kodkany B, et al. A prospective study of maternal, fetal and neonatal deaths in low- and middle-income countries. *Bull World Health Organ*. 2014;92:605-612. doi: 10.2471/BLT.13.127464
- 2. Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. *BMJ*. 2013;347:f6564. doi: 10.1136/bmj.f6564
- Ying W, Catov JM, Ouyang P. Hypertensive Disorders of Pregnancy and Future Maternal Cardiovascular Risk. *J Am Heart Assoc*. 2018;7:e009382. doi: 10.1161/JAHA.118.009382
- 4. Gupta M, Greene N, Kilpatrick SJ. Timely treatment of severe maternal hypertension and reduction in severe maternal morbidity. *Pregnancy Hypertens*. 2018;14:55-58. doi: 10.1016/j.preghy.2018.07.010
- Wright D, Rolnik DL, Syngelaki A, de Paco Matallana C, Machuca M, de Alvarado M, Mastrodima S, Tan MY, Shearing S, Persico N, et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. *Am J Obstet Gynecol*. 2018;218:612 e611-612 e616. doi: 10.1016/j.ajog.2018.02.014
- American College of O, Gynecologists' Committee on Practice B-O. Gestational
 Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. *Obstet Gynecol*.
 2020;135:e237-e260. doi: 10.1097/AOG.0000000000003891
- 7. NICE NIfHaCE. NICE guideline. Hypertension in pregnancy: diagnosis and management. 2019.

- 8. Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D, Singh M, Greco E, Wright A, Maclagan K, et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. *Ultrasound Obstet Gynecol*. 2018;51:743-750. doi: 10.1002/uog.19039
- 9. Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. *Am J Obstet Gynecol*. 2015;213:62 e61-62 e10. doi: 10.1016/j.ajog.2015.02.018
- 10. Li S, Wang Z, Vieira LA, Zheutlin AB, Ru B, Schadt E, Wang P, Copperman AB, Stone JL, Gross SJ, et al. Improving preeclampsia risk prediction by modeling pregnancy trajectories from routinely collected electronic medical record data. NPJ Digit Med. 2022;5:68. doi: 10.1038/s41746-022-00612-x
- Mello G, Parretti E, Ognibene A, Mecacci F, Cioni R, Scarselli G, Messeri G. Prediction of the development of pregnancy-induced hypertensive disorders in high-risk pregnant women by artificial neural networks. *Clin Chem Lab Med*. 2001;39:801-805. doi: 10.1515/CCLM.2001.132
- Maric I, Tsur A, Aghaeepour N, Montanari A, Stevenson DK, Shaw GM, Winn VD.
 Early prediction of preeclampsia via machine learning. *Am J Obstet Gynecol MFM*.
 2020;2:100100. doi: 10.1016/j.ajogmf.2020.100100
- 13. Li YX, Shen XP, Yang C, Cao ZZ, Du R, Yu MD, Wang JP, Wang M. Novelelectronic health records applied for prediction of pre-eclampsia: Machine-learning algorithms.

 *Pregnancy Hypertens. 2021;26:102-109. doi: 10.1016/j.preghy.2021.10.006

- Lie RT, Rasmussen S, Brunborg H, Gjessing HK, Lie-Nielsen E, Irgens LM. Fetal and maternal contributions to risk of pre-eclampsia: population based study. *BMJ*.
 1998;316:1343-1347. doi: 10.1136/bmj.316.7141.1343
- 15. Gray KJ, Kovacheva VP, Mirzakhani H, Bjonnes AC, Almoguera B, Wilson ML, Ingles SA, Lockwood CJ, Hakonarson H, McElrath TF, et al. Risk of pre-eclampsia in patients with a maternal genetic predisposition to common medical conditions: a case-control study. *BJOG*. 2021;128:55-65. doi: 10.1111/1471-0528.16441
- 16. Gray KJ, Kovacheva VP, Mirzakhani H, Bjonnes AC, Almoguera B, DeWan AT, Triche EW, Saftlas AF, Hoh J, Bodian DL, et al. Gene-Centric Analysis of Preeclampsia Identifies Maternal Association at PLEKHG1. *Hypertension*. 2018;72:408-416. doi: 10.1161/HYPERTENSIONAHA.117.10688
- 17. Steinthorsdottir V, McGinnis R, Williams NO, Stefansdottir L, Thorleifsson G, Shooter S, Fadista J, Sigurdsson JK, Auro KM, Berezina G, et al. Genetic predisposition to hypertension is associated with preeclampsia in European and Central Asian women. *Nat Commun.* 2020;11:5976. doi: 10.1038/s41467-020-19733-6
- 18. Honigberg MC, Chaffin M, Aragam K, Bhatt DL, Wood MJ, Sarma AA, Scott NS, Peloso GM, Natarajan P. Genetic Variation in Cardiometabolic Traits and Medication Targets and the Risk of Hypertensive Disorders of Pregnancy. *Circulation*. 2020;142:711-713. doi: 10.1161/CIRCULATIONAHA.120.047936
- 19. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, Ntritsos G, Dimou N, Cabrera CP, Karaman I, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nat Genet*. 2018;50:1412-1425. doi: 10.1038/s41588-018-0205-x

- 20. Kivioja A, Toivonen E, Tyrmi J, Ruotsalainen S, Ripatti S, Huhtala H, Jaaskelainen T, Heinonen S, Kajantie E, Kere J, et al. Increased Risk of Preeclampsia in Women With a Genetic Predisposition to Elevated Blood Pressure. *Hypertension*. 2022;79:2008-2015. doi: 10.1161/HYPERTENSIONAHA.122.18996
- 21. Clayton DG. Prediction and interaction in complex disease genetics: experience in type 1 diabetes. *PLoS Genet*. 2009;5:e1000540. doi: 10.1371/journal.pgen.1000540
- 22. Evans DM, Visscher PM, Wray NR. Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease risk. *Hum Mol Genet*. 2009;18:3525-3531. doi: 10.1093/hmg/ddp295
- 23. Giontella A, Sjogren M, Lotta LA, Overton JD, Baras A, Regeneron Genetics C, Minuz P, Fava C, Melander O. Clinical Evaluation of the Polygenetic Background of Blood Pressure in the Population-Based Setting. *Hypertension*. 2021;77:169-177. doi: 10.1161/HYPERTENSIONAHA.120.15449
- 24. Inouye M, Abraham G, Nelson CP, Wood AM, Sweeting MJ, Dudbridge F, Lai FY, Kaptoge S, Brozynska M, Wang T, et al. Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implications for Primary Prevention. *J Am Coll Cardiol*. 2018;72:1883-1893. doi: 10.1016/j.jacc.2018.07.079
- 25. Hindy G, Wiberg F, Almgren P, Melander O, Orho-Melander M. Polygenic Risk Score for Coronary Heart Disease Modifies the Elevated Risk by Cigarette Smoking for Disease Incidence. *Circ Genom Precis Med.* 2018;11:e001856. doi: 10.1161/CIRCGEN.117.001856

- 26. Cohen RY, Kovacheva VP. A Methodology For A Scalable, Collaborative, And Resource-Efficient Platform To Facilitate Healthcare AI Research.
 https://arxiv.org/pdf/2112.06883.pdf. 2021.
- 27. Gainer VS, Cagan A, Castro VM, Duey S, Ghosh B, Goodson AP, Goryachev S, Metta R, Wang TD, Wattanasin N, et al. The Biobank Portal for Partners Personalized Medicine: A Query Tool for Working with Consented Biobank Samples, Genotypes, and Phenotypes Using i2b2. *J Pers Med.* 2016;6. doi: 10.3390/jpm6010011
- 28. Ge T, Chen CY, Ni Y, Feng YA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nat Commun.* 2019;10:1776. doi: 10.1038/s41467-019-09718-5
- 29. Vaura F, Kauko A, Suvila K, Havulinna AS, Mars N, Salomaa V, FinnGen, Cheng S, Niiranen T. Polygenic Risk Scores Predict Hypertension Onset and Cardiovascular Risk. Hypertension. 2021;77:1119-1127. doi: 10.1161/HYPERTENSIONAHA.120.16471
- 30. Sandstrom A, Snowden JM, Bottai M, Stephansson O, Wikstrom AK. Routinely collected antenatal data for longitudinal prediction of preeclampsia in nulliparous women: a population-based study. *Sci Rep.* 2021;11:17973. doi: 10.1038/s41598-021-97465-3
- 31. Wright D, Tan MY, O'Gorman N, Poon LC, Syngelaki A, Wright A, Nicolaides KH.

 Predictive performance of the competing risk model in screening for preeclampsia. *Am J Obstet Gynecol*. 2019;220:199 e191-199 e113. doi: 10.1016/j.ajog.2018.11.1087
- 32. Park FJ, Leung CH, Poon LC, Williams PF, Rothwell SJ, Hyett JA. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy. *Aust N Z J Obstet Gynaecol*. 2013;53:532-539. doi: 10.1111/ajo.12126

- 33. Peterson RE, Kuchenbaecker K, Walters RK, Chen CY, Popejoy AB, Periyasamy S, Lam M, Iyegbe C, Strawbridge RJ, Brick L, et al. Genome-wide Association Studies in Ancestrally Diverse Populations: Opportunities, Methods, Pitfalls, and Recommendations. *Cell.* 2019;179:589-603. doi: 10.1016/j.cell.2019.08.051
- 34. SKLearn Documentation. https://scikit-learn.org/stable/modules/generated/sklearn.model_selection.StratifiedGroupKFold.html. 2022. Accessed Dec 6, 2022.